Kyungeon Kim

Ms. Kyungeon Kim

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
AMAnjali Sunil Menon
Anjali Sunil Menon
MVMadhini Vigneswaran
Madhini Vigneswaran
TZTina Lin Jie Zhang
Tina Lin Jie Zhang
VSVarsha Sreenivasan
Varsha Sreenivasan
KKKyungeon Kim
Kyungeon Kim
MMMartin James McKeown
Martin James McKeown
Impaired motor function is a defining characteristic of Parkinson’s disease (PD). Galvanic vestibular stimulation (GVS) has been proposed as a potential non-invasive intervention to enhance motor performance; however, its efficacy depends on both stimulation parameters and electrode configuration. In this study, we examined the effects of two-pole and three-pole GVS configurations, utilising different stimulation parameters, on motor performance in individuals with PD. Twelve participants with PD were administered eight distinct subthreshold amplitude-modulated GVS stimuli, along with sham stimulation, while performing a visuomotor target tracking task. Analysis of tracking error demonstrated substantial inter-individual variability in response to different stimuli and electrode configurations. While the three-pole configuration yielded superior motor performance in some cases, the two-pole configuration was more effective in others. The most effective overall stimulus across all subjects, characterised by an envelope frequency of 30 Hz and a carrier frequency of 110 Hz, improved motor performance by 25% relative to the sham stimulus. Moreover, tailoring the stimulation parameters to the individual further enhanced performance by an additional 24%. These findings suggest that GVS can yield significant motor improvements in individuals with PD. Furthermore, individualised optimisation of stimulation parameters, including the selection of the appropriate electrode configuration, may further enhance therapeutic efficacy.

Verified
Journal Article
Open access
PDF file
GGGabriella K. Guerra
Gabriella K. Guerra
SNShermyn Neo
Shermyn Neo
MMMaryam Mirian
Maryam Mirian
SSSepideh Hajipour Sardouie
Sepideh Hajipour Sardouie
EAEmad Arasteh
Emad Arasteh
MMMartin James McKeown
Martin James McKeown
Background: Wearing-off (WO) in Parkinson’s disease (PD) refers to the recurrence of motor and non-motor symptoms between levodopa doses. Its prevalence, inter-individual variability, and temporal relationship to medication remain incompletely characterized in real-world settings. Methods: Twenty-three PD participants with self-reported WO completed a digitized Wearing-Off Questionnaire-19 (WOQ-19) hourly during waking hours over three consecutive days (72 h), yielding 894 valid surveys. Symptom heterogeneity was quantified using the coefficient of variation (CV) and intraclass correlation coefficient (ICC). Symptom changes time-locked to medication intake were assessed using Cochran’s Q test. Results: Mean compliance was 91.86% ± 6.31%. All 19 WOQ-19 symptoms were endorsed at least once, with participants reporting a median of 8 distinct symptoms (IQR: 5–11). Prevalence differed significantly across symptoms (Kruskal–Wallis test, p < 0.001). Tremor was the most prevalent symptom overall, while other symptoms were rare, episodic, and highly variable across individuals. Participants’ relative symptom burden was consistent between Days 2 and 3 (Spearman’s rho = 0.682, p < 0.001), and diurnal worsening showed a non-significant positive trend (β = 0.031/hour, p = 0.117). Five symptoms showed significant peri-dose modulation: weakness, muscle cramping, experience of hot or cold, tremor, and abdominal discomfort (all p < 0.05). WO burden did not significantly correlate with standard clinical severity measures. Conclusions: WO symptom expression is highly heterogeneous across individuals but largely consistent from day to day within individuals. Weakness and experience of hot or cold are candidates for future wearable sensor-based studies of levodopa cycling, supporting individualized approaches to WO assessment in PD.